. The entire list of novel drugs approved in 2023 can be found in TableS1. Drugs that belong to different categories, such as small molecules, antibodies and proteins, and advanced therapy medicinal products (ATMP) and RNA are listed in Tables1–3, respectively. Vaccines are shown in Table4...
In 2023 to date, 51 novel drugs have been approved by the FDA to manage a broad spectrum of medical conditions – from Alzheimer’s disease and cancer to migraines, menopausal symptoms and post-partum depression. We highlight 10 from the list that are set to have a significant...
Here, we focus on the 12 drugs approved in 2022 with novel MoA targets (Table 1). These targets have not been modulated by any previously approved drug. Five targets, representing diverse protein classes, are modulated by small molecules. Notably, novel targets emerged in stagnant areas, such...
Inferring new indication of approved drugs is critical not only for the elucidation of the interaction mechanisms between these drugs and their associated diseases, but also for the development of drug therapy for various human diseases. This paper proposes a network-based approach to reveal the asso...
FDA's Center for Drug Evaluation and Research (CDER) reports that it has approved 35 novel new drugs in 2014. These 35 drugs include new molecular entities (NMEs) submitted to CDER in new drug applications (NDAs) and new therapeutic biologics submitted in biologics license applications (BLAs)....
Drug-disease associations include 593 drugs approved by the FDA that are within DrugBank [38], and 313 diseases registered in the Online Mendelian Inheritance in Man (OMIM) with 1933 validated DD associations. Both drugs and disease sets have similarities of around 1%. Drug pairwise similarity ...
in drug delivery routes and delivery vehicle research in the drug delivery system field have improved the efficacy of drugs used to treat nervous system diseases. The emergence of NDDSs has shown new clinical prospects in the formulation research of drugs. The development and maturity of drug ...
A biologic drug that closely resembles another biologic drug (called a reference drug) has been approved by the U.S. Food and Drug Administration (FDA). Biosimilars and reference drugs are made from living organisms, but they can be made in different ways and froms lightly different substances...
Here, our aim was to identify new BCRP inhibitors with clinical DDI potential amongst FDA-approved commonly prescribed drugs and anticancer drugs. A library of 232 drugs was studied with the vesicular transport assay, which is one of the FDA recommended in vitro test system for studying efflux ...
Cisplatin (CDDP; cis-diamminedichloroplatinum (II)) was the first inorganic platinum anticancer drug to be approved by the FDA and is one of the most common anticancer drugs available clinically.Citation12 Cisplatin is widely used in the treatment of lung, breast, liver, prostate, and cervical...